Type Whole antibody ATC code none ChemSpider none | Target EGFR CAS Number 1585973-65-4 | |
Source Chimeric/humanized hybrid (mouse/human) | ||
Depatuxizumab mafodotin (ABT-414) (INN) is an antibody-drug conjugate designed for the treatment of cancer. It is composed of an EGFR IGg1 monoclonal antibody (depatuxizumab) conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link.
In 2014, Orphan Drug Status was granted by the FDA for glioblastoma multiforme. It is in phase II/III clinical trials for glioblastoma, in phase II clinical trials for non-small cell lung cancer, and in phase I clinical trials for the treatment of other solid tumors. Phase I results were presented at ASCO in 2016.
This drug was developed by AbbVie.
References
Depatuxizumab mafodotin Wikipedia(Text) CC BY-SA